Cite
HARVARD Citation
Cohen, R. et al. (2020). RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. Journal for immunotherapy of cancer. 8 (2), p. . [Online].